Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Styl ...

Key Takeaways COO Q3 revenues are likely to be $982M, up 5.4% y/y, with projected EPS growth of 8.2%.COO benefits from strong MyDay, Clarity, and Biofinity demand across global markets.COO's CSI faces fertility weakness, partly offset by minimally-invasive surgical and OVP Surgical growth.The Cooper Companies, Inc.’s (COO) third-quarter fiscal 2025 results are scheduled to be released on Aug. 27, after the closing bell.In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by ...

 Calgary, Alberta – TheNewswire - August 26, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it has completed the one-week postoperative examination of the first patients who were implanted with the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”).  All patients are recovering well, and no complications have been observed.  With this important milestone achieved, a ...

Newly-formed PAVmed subsidiary to license endoscopic imaging technology designed to identify and facilitate ablative treatment of esophageal dysplasiaLucid Diagnostics to collaborate with PAVmed as a strategic and equity partner on the technologyNEW YORK, Aug. 26, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors,  today announced that it has executed ...

Izotropic Announces Non-Brokered Private Placement & Extends WarrantsAugust 26, 2025 8:00 AM EDT | Source: Izotropic CorporationVancouver, British Columbia and Sacramento, California--(Newsfile Corp. - August 26, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announ ...

Data from acute and chronic pressure-volume loop studies support the mechanism of action and show a favorable impact of AVIM therapy on blood pressure and cardiovascular hemodynamicsAVIM therapy drove statistically significant reductions in systolic blood pressure, intra-cardiac volumes, total peripheral resistance and stroke work, with no adverse impact on stroke volume or contractility.Orchestra BioMed and Medtronic (NYSE: MDT) have a strategic collaboration for the development of AVIM therapy for treatme ...

Funding to Support Continued Growth of Focal One® Robotic HIFU AUSTIN, Texas, August 26, 2025 - EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced execution of a letter of intent for EUR 36 million credit facility with the European Investment Bank (EIB). Proceeds from this financing will support the continued expansion of Focal One® Robotic HIFU in Focal Therapy, the fastest-growing treatment category for early-stage prostate cancer whi ...

NEW YORK, Aug. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Align Technology, Inc. ("Align" or the "Company") (NASDAQ: ALGN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  The investigation concerns whether Align and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On July 30, 2025, Ali ...

Medical Device Firm's Stock Spikes After Pivoting to Solana With $400 Million Treasury Plan► https://t.co/Fn0nAHk1LD https://t.co/Fn0nAHk1LD ...

Core Insights - OrthoPediatrics Corp. announced the appointment of Kelly Fischer to its Board of Directors, effective August 8, 2025, alongside the retirement of Terry Schlotterback from the board on the same date [1][2]. Group 1: Board Changes - Kelly Fischer brings extensive financial leadership experience from her role as Senior Vice President and Chief Financial Officer at Cook Medical, a multibillion-dollar medical device company [2]. - Terry Schlotterback has served over fifteen years as a Director and Chairman of the Board, contributing significantly to the company's establishment as a leader in pediatric orthopedics [2]. Group 2: Company Strategy and Vision - Kelly Fischer expressed her commitment to supporting OrthoPediatrics' strategy to increase market share, launch new technologies, and expand the specialty bracing franchise efficiently [3]. - The company aims to help one million children by advancing its offerings in the pediatric orthopedic field [3]. Group 3: Company Overview - Founded in 2006, OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 80 products across trauma and deformity, scoliosis, and sports medicine categories [4]. - The company's global sales organization distributes its products in the United States and over 70 countries, emphasizing its commitment to improving the lives of children with orthopedic conditions [4].